Pharmaceuticals News and Research

RSS

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food & Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for Omapro™ (omacetaxine mepesuccinate) for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

10 Nov 2009

House healthcare bill is radically off the mark: Cinergy Health

Cinergy Health, a nationwide provider of guaranteed issue health insurance benefit programs for the consumer market, expressed its concern for the house healthcare bill that passed Saturday, November 7th.

9 Nov 2009

Labcyte to receive $5.5 million from Hercules Technology Growth Capital

Hercules Technology Growth Capital, Inc. (NASDAQ: HTGC), the leading specialty finance company providing venture debt and equity to venture capital and private equity-backed technology and life science companies at all stages of development, today announced that it has committed to provide Labcyte, Inc. (www.labcyte.com) $5.5 million in credit facilities.

9 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Zosano Pharma, Inc., a privately held pharmaceutical company developing products using a novel transdermal delivery technology, announced publication in the current issue of the Journal of Clinical Endocrinology and Metabolism of results from a positive phase 2 study of its rapid-delivery transdermal patch (ZP-PTH) for the treatment of postmenopausal osteoporosis.

9 Nov 2009

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.

9 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

Covidien contraindicates use of its Optimark gadoversetamide injection

Covidien, a leading global provider of healthcare products, today announced that it will voluntarily contraindicate the use of its Optimark™ gadoversetamide injection, a gadolinium-based contrast agent (GBCA), in magnetic resonance imaging (MRI) procedures involving patients with severe renal impairment.

9 Nov 2009

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that it has entered into a definitive agreement to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million plus an additional amount of up to $27 million based on success milestones. Enzon will also receive royalties of 5 to 10 percent on incremental net sales above a 2009 baseline amount from Enzon’s four marketed specialty pharmaceutical products through 2014.

9 Nov 2009

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2008, human epidermal growth factor receptor 2 (HER2) targeting therapies -- which include Roche/Chugai's Herceptin and GlaxoSmithKline/Nippon Kayaku's Tykerb/Tyverb -- were the highest-selling drug class in breast cancer treatment.

9 Nov 2009

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2009.

9 Nov 2009

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

ISTA Pharmaceuticals, Inc., today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL.

9 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Angiotech Pharmaceuticals, Inc. today announced its financial results for the third quarter ended September 30, 2009.

9 Nov 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009.

9 Nov 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Caliper Life Sciences, Inc. today reported results for its third quarter ended September 30, 2009. GAAP revenues increased by 4% to $32.2 million, from non-GAAP revenues of $31.0 million in the same period of 2008, which represents GAAP revenue of $34.0 million in the third quarter of 2008 reduced by $3.0 million for the impact of divested product lines.

9 Nov 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company’s strategic alliance with GlaxoSmithKline.

9 Nov 2009

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement to acquire the manufacturing license in China of Rosuvastatin from Tianjin Tianda Pharmaceutical Co., Ltd. ("Tianda").

9 Nov 2009

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.

9 Nov 2009

Pharmaceuticals News and Research

FDA accepts ChemGenex Pharmaceuticals' NDA for Omapro

House healthcare bill is radically off the mark: Cinergy Health

Labcyte to receive $5.5 million from Hercules Technology Growth Capital

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Shire's INTUNIV for treating ADHD now available in the U.S.

Positive study data from Zosano Pharma's ZP-PTH transdermal patch for treating osteoporosis

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

CytRx reports financial results for the three months and nine months ended September 30, 2009

Covidien contraindicates use of its Optimark gadoversetamide injection

Enzon Announces to sell its specialty pharmaceutical business to the sigma-tau Group for $300 million

Decision Resources forecasts sales of HER2-targeting agents to grow by 3.3% per year

Progenics Pharmaceuticals reports financial results for the third quarter of 2009

ISTA Pharmaceuticals presents additional data from its Bepreve Phase 3 clinical studies

NanoViricides to present data on its in vivo studies against influenza

Angiotech Pharmaceuticals reports financial results for the third quarter ended September 30, 2009

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

Caliper Life Sciences announces financial results for third quarter ended September 30, 2009

Concert Pharmaceuticals commences Phase 1b clinical study of its CTP-518 HIV protease inhibitor

Simcere Pharmaceutical Group signs agreement to acquire manufacturing license from Tianjin Tianda Pharmaceutical

SuperGen to stage presentations to review clinical and non-clinical advances in different compounds

Event guide: World ADC Asia eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring